Package Leaflet: Information for the Patient
Aciclovir Noridem500 mg powder for solution for infusionEFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Aciclovir Noridem contains the active substance aciclovir. This medicine is a direct-acting antiviral agent (destroys or stops the growth of viruses that cause herpes zoster or herpes).
It is used to treat certain infections caused by the herpes virus and certain forms of chickenpox and herpes zoster (a viral disease characterized by a painful rash, for example, in the eye).
Do not takeAciclovir Noridem
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using this medicine.
Other medicines andAciclovir Noridem
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Pregnancy, breastfeedingand fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You should not take this medicine during pregnancy unless your doctor advises you to.
If you become pregnant during treatment, inform your doctor as soon as possible, as they will need to decide whether you should continue treatment.
Avoid breastfeeding during treatment with aciclovir as it may be excreted in breast milk.
Driving and using machines
Your doctor will assess your ability to drive vehicles and use machines based on your health and certain side effects, especially in the nervous system, that may occur during treatment (see Section 4: Possible side effects).
Aciclovir Noridemcontains sodium
This medicine contains 52.2 mg of sodium (main component of table/cooking salt) per vial. This is equivalent to 2.6% of the maximum recommended daily sodium intake for an adult.
This medicine should never be administered by yourself. It will always be administered by a person who is properly qualified to do so.
Posology
The dosage is determined based on the condition being treated and the patient's age and weight.
Use in patients with kidney problems
Caution is recommended when administering aciclovir by infusion to patients with renal insufficiency.
Method of administration
This medicine will be administered by a healthcare professional, who will inject it into a vein (strict intravenous (IV) use).
Duration of treatment
The duration of treatment is usually 5 to 10 days. It should be adjusted according to the patient's condition and response to treatment. In the case of neonatal herpes and depending on the indication, this duration may be 14 or 21 days.
If you are given moreAciclovir Noridemthan you should
Talk to your doctor immediately.
In some situations (for example, if you have kidney problems), neurological disorders (see section 4: Possible side effects) may occur.
In case of overdose or accidental ingestion, talk to your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
These side effects are classified from the most frequent to the least frequent.
Common:(may affect up to 1 in 10 people)
These effects usually disappear when treatment is discontinued.
Frequency not known:(frequency cannot be estimated from the available data)
The risk of acute kidney failure is caused by an overdose and/or dehydration, or by combination with medicines that are toxic to the kidneys.
These risk factors should be controlled, regardless of the patient's age. The risk of kidney problems can be avoided by following the posology, precautions for use (especially maintaining adequate hydration), and a slow administration rate.
Other side effects
Frequency not known:(frequency cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System, www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial and carton after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
After reconstitution:
Chemical and physical stability in use has been demonstrated for 24 hours at 23°C to 27°C under artificial light and 2°C to 8°C when dissolved in 20 ml of water for injections or in a 9 mg/ml (0.9%) sodium chloride injection solution.
After dilution:
Chemical and physical stability in use has been demonstrated for 12 hours at 23°C to 27°C at an Aciclovir concentration of 5.0 mg/ml after dilution with the compatible solutions mentioned in the section Information for healthcare professionals, Preparation and handling.
From a microbiological point of view, the product should be used immediately. If not used immediately, the in-use storage times and conditions before use are the responsibility of the user and would normally not exceed 24 hours at 2°C to 8°C or the times stated above for chemical and physical stability in use, whichever is the shorter, unless the opening/reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition ofAciclovir Noridem
Appearance ofAciclovir Noridemand Container Content
Aciclovir Noridem powder for solution for infusion is presented in 20 ml type I colorless glass vials, containing a white or off-white powder, closed with a 20 mm bromobutyl stopper and sealed with a 20 mm aluminum cap, with a yellow plastic tear-off cap.
Container sizes: 1, 5 or 10 vials.
Only some container sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Noridem Enterprises Ltd.
Evagorou & Makariou
Mitsi Building 3, Office 115
1065 Nicosia, Cyprus
Manufacturer
DEMO S.A. PHARMACEUTICAL INDUSTRY
21st Km National Road Athens-Lamia.
14568 Greece
T:+30 210 8161802, F:+30 2108161587.
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Germany | Aciclovir Noridem 500 mg Powder for solution for infusion |
Romania | Aciclovir Noridem 500 mg Powder for solution for infusion |
Czech Republic | Aciclovir Noridem |
Croatia | Aciklovir Noridem 500 mg powder for solution for infusion |
Austria | Aciclovir Noridem 500 mg Powder for solution for infusion |
Italy | Aciclovir Noridem |
Poland | Aciclovir Noridem |
Slovakia France Spain Portugal Netherlands Hungary Slovenia | Aciclovir Noridem 500 mg Powder for solution for infusion Aciclovir Noridem 500 mg Powder for solution for infusion Aciclovir Noridem 500 mg powder for solution for infusion Aciclovir Noridem Aciclovir Noridem 500 mg Powder for solution for infusion Aciclovir Noridem 500 mg powder for solution for infusion Aciklovir Noridem 500 mg powder for solution for infusion |
Date of last revision of this leaflet: November 2022
---------------------------------------------------------------------------------------------------------------------------
The following information is intended for healthcare professionals only:
Preparation and Handling
It should be prepared immediately before use. Unused solution should be discarded.
Reconstitution:
Aciclovir Noridem should be reconstituted using the following volumes of water for injectable preparations or 9 mg/ml (0.9%) sodium chloride solution for injection to obtain a solution containing 25 mg of aciclovir per ml:
Volume of liquid for reconstitution formulation
500 mg vial 20 ml
Based on the calculated dose, the appropriate number and concentration of vials to be used should be determined.
To reconstitute each vial, the recommended volume of infusion liquid should be added and shaken gently until the vial contents are completely dissolved.
Administration
The required dose of Aciclovir Noridem should be administered by slow intravenous infusion over a period of one hour.
After reconstitution, Aciclovir Noridem can be administered using a controlled-rate infusion pump. Alternatively, the reconstituted solution can be further diluted to give an aciclovir concentration of no more than 5 mg/ml (0.5% w/v) for infusion.
The required volume of reconstituted solution should be added to the chosen infusion solution, as recommended below, and shaken well to ensure adequate mixing.
For children and neonates, in whom the volume of infusion liquid should be kept to a minimum, it is recommended that the dilution be based on 4 ml of reconstituted solution (100 mg of aciclovir) added to 20 ml of infusion liquid.
For adults, it is recommended to use infusion bags containing 100 ml of infusion liquid, even if this provides a substantially lower aciclovir concentration than 0.5% w/v. Therefore, a 100 ml infusion bag can be used for any dose between 250 mg and 500 mg of aciclovir (10 and 20 ml of reconstituted solution), but a second bag should be used for doses between 500 mg and 1000 mg.
When diluted according to the recommended schemes, Aciclovir Noridem is known to be compatible with the following infusion liquids:
Aciclovir Noridem, when diluted according to the above scheme, provides an aciclovir concentration not exceeding 0.5% w/v
Since no antimicrobial preservative is included, reconstitution and dilution must be carried out under completely aseptic conditions, immediately before use, and any unused solution should be discarded.
Reconstituted or diluted solutions should not be refrigerated.
If visible turbidity or crystallization appears in the solution before or during infusion, the preparation should be discarded.
Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.
Incompatibilities
This medicinal product should not be mixed with other medicinal products except those mentioned in the Administration section.
Posology and Method of Administration
Posology
The dose for patients with normal renal function is indicated below. In patients with abnormal renal function, the posology should be adapted according to the level of renal insufficiency (see section Patients with renal insufficiency).
Regarding recommendations on the duration of treatment, see the section Duration of treatment.
Posology in patients with normal renal function
Adults and adolescents (>12 years)
Patients with obesity should be given the recommended dose for adults based on ideal body weight rather than actual body weight.
Pediatric population
Children over 3 months of age
In children between 3 months and 12 years of age, the dose should be calculated according to body weight.
Neonates
In neonates and infants up to 3 months of age, the dose is calculated based on body weight.
Posology in patients with renal insufficiency
The interval between doses and posology should be adjusted according to creatinine clearance in ml/min for adults and adolescents and in ml/min/1.73 m2 for infants and children under 13 years. Caution is recommended when administering aciclovir by infusion to patients with renal insufficiency. In such patients, care should be taken to ensure adequate fluid intake.
The following dose adjustments are proposed.
Recommended dose adjustment in adults and adolescents > 12 years with renal insufficiency:
Creatinine clearance | Recommended unit dose and dosing frequency according to indication | |
Infections due to VHS or VVZ (except meningoencephalitis) | Infections due to VZV in immunocompromised patients or herpetic meningoencephalitis | |
25-50ml/min | 5 mg/kg of body weight every 12 hours | 10 mg/kg of body weight every 12 hours |
10-25ml/min | 5 mg/kg of body weight every 24 hours | 10 mg/kg of body weight every 24 hours |
0(anuria) to 10ml/min | 2.5 mg/kg of body weight every 24 hours | 5 mg/kg of body weight every 24 hours |
Patients on hemodialysis | 2.5 mg/kg of body weight every 24 hours and after hemodialysis | 5 mg/kg of body weight every 24 hours and after hemodialysis |
Dose adjustment in children ≤ 12 years, infants and neonates with renal insufficiency:
Creatinine clearance (ml/min/1.73 m2) | Recommended unit dose and dosing frequency according to indication | |
In infants and children 3months or older | ||
Infectiondue to VHS or VVZ (except meningoencephalitis) Infection due to VVZ | Infections due to VZV in immunocompromised patients or herpetic meningoencephalitis | |
25‑50ml/min/1.73m2 | 10 mg/kg of body weight twice daily | 20 mg/kg of body weight twice daily |
10-25ml/min/1.73m2 | 5 mg/kg of body weight twice daily | 10 mg/kg of body weight twice daily |
0(anuria) to 10ml/min/1.73m2 | 2.5 mg/kg of body weight twice daily | 5 mg/kg of body weight twice daily |
Patients on hemodialysis | 2.5 mg/kg of body weight twice daily after hemodialysis | 5 mg/kg of body weight twice daily after hemodialysis |
Older adults
The possibility of renal insufficiency should be considered in older adults and the posology adjusted according to creatinine clearance (see section "Posology in patients with renal insufficiency").
Adequate fluid intake should be ensured.
Duration of Treatment
The duration of treatment is generally 5 days, but may be adjusted according to the patient's condition and response to treatment. The duration is:
The duration of prophylactic treatment with Aciclovir Noridem is determined by the duration of the risk period.
Method of Administration
Strictly intravenous route:
Each dose should be injected slowly intravenously (by pump or infusion) for at least one hour.
To consult the instructions for reconstitution of the medicinal product before administration, see the section Preparation and Handling.
Overdose
Symptoms and signs
Overdose of intravenous aciclovir has caused increased serum creatinine, blood urea, and consequent renal insufficiency. Neurological effects such as confusion, hallucinations, agitation, seizures, and coma have been described in association with overdose.
Treatment
Patients should be closely monitored for any signs of toxicity.
Hemodialysis significantly increases the elimination of aciclovir from the bloodstream and may be considered as a treatment option in cases of symptomatic overdose.